Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Epargny Metz-Tessy, France Clinical Trials

A listing of Epargny Metz-Tessy, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (77) clinical trials

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

This study is a multicenter phase II trial which primary objective is to assess the anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199, venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts: relapsed/refractory follicular lymphoma (FL) patients relapsed/refractory aggressive (DLBCL) lymphoma patients relapsed/refractory other indolent (iNHL) …

Phase

0.0 miles

Learn More »

Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects

Double-blind randomised, parallel-group, three-arm, multicentre, placebo-controlled study The primary objective is to demonstrate the superiority of the combination of Periactine (cyproheptadine 8 mg/day or 12 mg/day) and Alpress (prazosin 5 mg/day or 10 mg/day) over placebo on the reduction of the total alcohol consumption (TAC), in alcohol-dependent patients. 180 patients …

Phase

0.0 miles

Learn More »

Trial of Treatments for COVID-19 in Hospitalized Adults

This study is a multi-centre, adaptive, randomized, open clinical trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults. The study is a multi-centre/country trial that will be conducted in various sites in Europe with Inserm as sponsor. Adults (18 year-old) hospitalized for COVID-19 with SpO2 94% …

Phase

0.0 miles

Learn More »

Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection

Infection with the SARS-Cov-2 virus, responsible of severe acute respiratory distress syndrome (SARS), is an emerging infectious disease called Covid-19 and declared as pandemic by the World Health Organization on March 11, 2020. This pandemic is responsible of significant mortality. In France, several thousand patients are hospitalized in intensive care …

Phase

0.0 miles

Learn More »

Host-pathogen Interactions During SARS-CoV-2 Infection

The new Severe acute respiratory syndrome coronavirus (SARS-CoV-2) named coronavirus disease 2019 (COVID-19) is currently responsible for a pandemic spread of febrile respiratory infections, responsible for a veritable global health crisis. In adults, several evolutionary patterns are observed: i) a/pauci-symptomatic forms; ii) severe forms immediately linked to rare extensive viral …

Phase N/A

0.0 miles

Learn More »

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.

Phase

0.61 miles

Learn More »

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Currently, there is no standard treatment for patients with recurrent or refractory peripheral T-cell lymphoma who relapse after a first line of cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (CHOP) treatment. Chemotherapies such as gemcitabine are used as monotherapy but the results alone are insufficient. In addition, there is no approved monotherapy …

Phase

0.61 miles

Learn More »

ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE

As the proportion of oral anticancer treatments is continuously increasing, adherence appears as a major issue for patients' outcomes. Poor adherence affects particularly geriatric patients due among others to polypharmacy or cognitive impairment. Thus, the need for educational programs in this population has been regularly emphasized. PRESTAGE educational program was …

Phase N/A

0.61 miles

Learn More »

Montelukast for Patients With Obstructive Sleep Apnea Syndrome

Obstructive Sleep Apnea Syndrome (OSAS) induces low-grade systemic and vascular inflammation, including activation of the leukotriene pathway. In apneic patients, the urinary excretion of LTE4, a systemic marker of CysLT pathway activation, is increased in relation to the severity of OSAS and it's an independent predictor of cardiovascular risk event …

Phase

0.61 miles

Learn More »

Short Duration Treatment of Non-severe Community Acquired Pneumonia

To investigate the non inferiority of a short lasting antibiotic treatment (3 days) when compared to a long lasting antibiotic treatment (8 days), at Day 15 after the beginning of treatment in terms of clinical efficacy, in adults admitted to emergency services for a non severe Community Acquired Pneumonia (PAC), …

Phase

0.61 miles

Learn More »